Founded in 2012, MindMaze is a global leader in brain technology with a mission to accelerate humanity's ability to recover, learn and adapt. With over a decade of work at the intersection of neuroscience, biosensing, engineering, mixed reality and artificial intelligence, MindMaze has enhanced the recovery potential of patients with neurological diseases.

The company combines FDA cleared and CE marked digital therapeutics with best-in-class motion analytics, AI and cloud technologies to create the universal platform for brain health.

MindMaze Labs, the enterprising R&D division, brings ground-breaking neuroscience to everyday life, empowering the next generation of human-machine interfaces.

Key milestones include seminal scientific work published in Science, awards such as the Pfizer Foundation award for Fundamental Research in Neuroscience, significant grants for development, and expansion with US operations and international partnerships.

MindMaze has become the first Swiss unicorn in its field, with FDA and CE certifications, numerous patents, and acquisitions that bolster its healthcare and AI capabilities.

MindMaze operates two core divisions: Healthcare, focusing on FDA and CE cleared digital therapeutics for neurorehabilitation, and Labs, an advanced neuroscience R&D hub aimed at improving everyday life.